mRNA as a critical area for pharma innovation

The value of mRNA licensing agreements has skyrocketed by a staggering 800% between 2019 and 2024, driven by the success of mRNA-based COVID-19 vaccines and growing confidence in the technology’s broader applications. This surge, highlighted by GlobalData, a leading data and analytics firm, underscores the pharmaceutical industry’s commitment to exploring mRNA’s potential beyond vaccines, particularly in addressing unmet medical needs. mRNA’s transformative impact on vaccine development Ophelia Chan, Senior Analyst at GlobalData, points to the COVID-19 pandemic as the turning point for mRNA technology. “The pandemic showcased mRNA’s key advantages in vaccine development, including rapid production, precise immune targeting, and streamlined manufacturing processes. These factors were crucial to the success of mRNA-based COVID-19 vaccines, like Pfizer’s Comirnaty, the first mRNA vaccine approved by the FDA in August 2021.” Since then, pharmaceutical companies have increasingly recognized mRNA’s potential in a wide range of treatments, with licensing deals reflecting this confidence. According to GlobalData’s Drugs Database,...